Home LiteratureArticle Details
PMID: 18473850 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Review

Advanced glycation end products and insulin resistance.

Current pharmaceutical design ·Vol. 14 ·No. 10 ·2008-00-00 ·Pages 987-9

Unoki H, Yamagishi S

Abstract

Non-enzymatic modification of proteins by reducing sugars, a process that is also known as Maillard reaction, leads to the formation of advanced glycation end products (AGEs) in vivo. There is a growing body of evidence that formation and accumulation of AGEs progress during normal aging, and at an extremely accelerated rate under diabetes, thus being involved in the pathogenesis of diabetic vascular complications. Further, recently, engagement of their receptor, RAGE with AGEs is shown to activate its down-stream signaling and evoke oxidative stress and inflammation in diabetes. Since oxidative stress generation and inflammation are closely associated with insulin resistance as well, it is conceivable that the AGEs-RAGE system could play a role in the pathogenesis of insulin resistance and subsequently the development of diabetes. In this paper, we review the role of the AGEs-RAGE system in insulin resistance, especially focusing on its effects on the insulin-signaling pathways in skeletal muscles and adipocytes.

MeSH Terms
Adipocytes/metabolism Animals Diabetes Mellitus/etiology,metabolism Dietary Fats/metabolism Eating Glycation End Products, Advanced/antagonists & inhibitors,metabolism Humans Inflammation/metabolism Insulin Resistance Muscle, Skeletal/metabolism Obesity/etiology,metabolism Oxidative Stress Receptor for Advanced Glycation End Products Receptor, Insulin/metabolism Receptors, Immunologic/metabolism
Chemicals
Dietary Fats Glycation End Products, Advanced Receptor for Advanced Glycation End Products Receptors, Immunologic Receptor, Insulin
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Unoki Hiroyuki
Laboratory for Diabetic Nephropathy, SNP Research Center, RIKEN, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan. hi-unoki@src.riken.jp
Yamagishi Sho-ichi
Article Info
Journal
Current pharmaceutical design
Abbr.
Curr Pharm Des
ISSN
1873-4286
Published
2008-00-00
Pages
987-9
Language
English
Region
United Arab Emirates
NLM ID
9602487
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com